ActRIIA (ACVR2A) and ActRIIB (ACVR2B) are members of the transforming growth factor β (TGF-β) receptor family, including activin A, activin B, BMP7, BMP9, BMP10, GDF1, GDF8 (myostatin), GDF11, and Nodal. ALK4 and ALK7 are principal type I TGF-β receptor family members for activin A and activin B, respectively. Bimagrumab is a human monoclonal antibody that can block the activin II type receptor (ActRII) to regulate skeletal muscle growth.Activin A Reporter Cell Line is a luciferase reporter gene cell line that uses Activin A as the agonist for activity detection (specifically for Activin A activity; does not differentiate between ACVR2A and ACVR2B). When Activin A binds to the receptor, it activates the signal pathway, leading to the expression of luciferase, with luciferase readings representing the activation effect of the signal pathway. Moreover, this activation effect can also be blocked by inhibitory antibodies such as Bimagrumab, making it suitable for evaluating the effects of related drugs in vitro.
